Skip Navigation


Human Reproduction Update Advance Access originally published online on March 31, 2006
Human Reproduction Update 2006 12(3):328-329; doi:10.1093/humupd/dml008
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
12/3/328    most recent
dml008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Griesinger, G.
Right arrow Articles by Kolibianakis, E.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Griesinger, G.
Right arrow Articles by Kolibianakis, E.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Letter to the Editor

Reply: Agonist trigger in the context of OHSS prevention: primum non nocere

G. Griesinger1,3, K. Diedrich1, P. Devroey2 and E.M. Kolibianakis2

1 Department of Obstetrics and Gynecology, University Clinic of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany and 2 Centre of Reproductive Medicine, Dutch Speaking, Brussels Free University, Brussels, Belgium

3 To whom correspondence should be addressed at: Ratzeburger Allee 160, 23538 Luebeck. E-mail: georg.griesinger@frauenklinik.uniluebeck.de

The first 10% of the full text of this article appears below.

Sir,

We thank Dr Kol for his interest in our recent systematic review (Griesinger et al., 2005Go) on GnRH agonist usage for triggering final oocyte maturation in IVF patients.

In his letter, Dr Kol scrutinizes the necessity to test GnRH agonist triggering in normal responders at all, although he acknowledges that a randomized controlled trial (RCT) in ovarian hyperstimulation syndrome (OHSS)-risk patients is unethical. Still, Dr Kol states that exploring GnRH agonist triggering in normal responder patients came . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?